 Diabetes Mellitus, Type 2
"Diabetes Mellitus, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Descriptor ID |
D003924
|
| MeSH Number(s) |
C18.452.394.750.149 C19.246.300
|
| Concept/Terms |
Diabetes Mellitus, Type 2- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Ketosis-Resistant
- Diabetes Mellitus, Ketosis Resistant
- Ketosis-Resistant Diabetes Mellitus
- Diabetes Mellitus, Maturity-Onset
- Diabetes Mellitus, Maturity Onset
- Diabetes Mellitus, Non Insulin Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
- Non-Insulin-Dependent Diabetes Mellitus
- Type 2 Diabetes Mellitus
- Diabetes Mellitus, Slow-Onset
- Diabetes Mellitus, Slow Onset
- Slow-Onset Diabetes Mellitus
- Diabetes Mellitus, Stable
- Stable Diabetes Mellitus
- Diabetes Mellitus, Type II
- Maturity-Onset Diabetes Mellitus
- Maturity Onset Diabetes Mellitus
- MODY
- NIDDM
- Diabetes Mellitus, Adult-Onset
- Adult-Onset Diabetes Mellitus
- Diabetes Mellitus, Adult Onset
- Diabetes Mellitus, Noninsulin Dependent
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Type 2".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Type 2".
This graph shows the total number of publications written about "Diabetes Mellitus, Type 2" by people in this website by year, and whether "Diabetes Mellitus, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1984 | 0 | 2 | 2 | | 1986 | 1 | 0 | 1 | | 1988 | 6 | 0 | 6 | | 1989 | 4 | 0 | 4 | | 1990 | 4 | 1 | 5 | | 1991 | 3 | 0 | 3 | | 1992 | 11 | 1 | 12 | | 1993 | 6 | 1 | 7 | | 1994 | 10 | 2 | 12 | | 1995 | 20 | 3 | 23 | | 1996 | 22 | 1 | 23 | | 1997 | 18 | 3 | 21 | | 1998 | 6 | 4 | 10 | | 1999 | 5 | 1 | 6 | | 2000 | 25 | 6 | 31 | | 2001 | 11 | 4 | 15 | | 2002 | 18 | 5 | 23 | | 2003 | 7 | 6 | 13 | | 2004 | 21 | 5 | 26 | | 2005 | 27 | 4 | 31 | | 2006 | 28 | 6 | 34 | | 2007 | 20 | 6 | 26 | | 2008 | 27 | 8 | 35 | | 2009 | 19 | 9 | 28 | | 2010 | 25 | 6 | 31 | | 2011 | 30 | 9 | 39 | | 2012 | 26 | 6 | 32 | | 2013 | 34 | 4 | 38 | | 2014 | 42 | 6 | 48 | | 2015 | 30 | 5 | 35 | | 2016 | 40 | 4 | 44 | | 2017 | 26 | 6 | 32 | | 2018 | 38 | 7 | 45 | | 2019 | 30 | 3 | 33 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Diabetes Mellitus, Type 2" by people in Profiles.
-
Mastracci TL, Colvin SC, Padgett LR, Mirmira RG. Hypusinated eIF5A is expressed in the pancreas and spleen of individuals with type 1 and type 2 diabetes. PLoS One. 2020; 15(3):e0230627.
-
Philipson LH. Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 02; 16(2):79-80.
-
Despa F, Goldstein LB, Biessels GJ. Amylin as a Potential Link between Type 2 Diabetes and Alzheimer Disease. Ann Neurol. 2020 03; 87(3):486.
-
Thornton PL, Kumanyika SK, Gregg EW, Araneta MR, Baskin ML, Chin MH, Crespo CJ, de Groot M, Garcia DO, Haire-Joshu D, Heisler M, Hill-Briggs F, Ladapo JA, Lindberg NM, Manson SM, Marrero DG, Peek ME, Shields AE, Tate DF, Mangione CM. New research directions on disparities in obesity and type 2 diabetes. Ann N Y Acad Sci. 2020 02; 1461(1):5-24.
-
Baghikar S, Benitez A, Fernandez Piñeros P, Gao Y, Baig AA. Factors Impacting Adherence to Diabetes Medication Among Urban, Low Income Mexican-Americans with Diabetes. J Immigr Minor Health. 2019 Dec; 21(6):1334-1341.
-
Laiteerapong N, Ham SA, Nathan AG, Sargis RM, Quinn MT, Huang ES. National physician survey on glycemic goals and medical decision making for patients with type 2 diabetes. Medicine (Baltimore). 2019 Dec; 98(51):e18491.
-
Mayberry LS, Lyles CR, Oldenburg B, Osborn CY, Parks M, Peek ME. mHealth Interventions for Disadvantaged and Vulnerable People with Type 2 Diabetes. Curr Diab Rep. 2019 11 25; 19(12):148.
-
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
-
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):345-356.
-
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol. 2019; 50(5):333-344.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|